Shang‐Yin Wu

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

The interplay between oral microbiome, lifestyle factors and genetic polymorphisms in the risk of oral squamous cell carcinoma

Jenn-Ren Hsiao, Chan‐Chi Chang, Wei-Ting Lee et al. · Carcinogenesis · 2018 · 151 citations · Full text

Dentistry, Oral Biology, Oral Pathology +17

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

D. Ross Camidge, Jair Bar, Hidehito Horinouchi et al. · Journal of Clinical Oncology · 2024 · 135 citations · Full text

Medicine, Oncology, Pharmacology +17

Investigating the association between oral hygiene and head and neck cancer

Jeffrey S. Chang, Hung‐I Lo, Tung-Yiu Wong et al. · Oral Oncology · 2013 · 127 citations

Dentistry, Dental Hygiene, Oncology +14